ライフサイエンスコーパス: inclusion body myositis

1 itis or dermatomyositis, and 2 families with inclusion body myositis.

2 A alterations may be accelerated in sporadic inclusion body myositis.

3 group demonstrated histological features of inclusion body myositis.

4 proposed criteria for definite and possible inclusion body myositis.

5 stological confirmation may nonetheless have inclusion body myositis.

6 scles, quadriceps, and ankle dorsiflexors in inclusion body myositis.

7 ly definite by MRC criteria was required for inclusion body myositis.

8 genotype confers the highest disease risk in inclusion body myositis.

9 r focus on polymyositis, dermatomyositis and inclusion body myositis.

10 mulate intracellularly in some patients with inclusion body myositis.

11 includes polymyositis, dermatomyositis, and inclusion body myositis.

12 omprising dermatomyositis, polymyositis, and inclusion body myositis.

13 sent key early events in the pathogenesis of inclusion body myositis.

14 ntotemporal lobar degeneration, and sporadic inclusion body myositis.

15 s are potential disease activity sensors for inclusion body myositis.

16 vided into dermatomyositis, polymyositis and inclusion body myositis.

17 ive muscle disease of aging humans, sporadic inclusion body myositis.

18 ulates early in Alzheimer's disease (AD) and inclusion body myositis.

19 l (3.3%, 1.8-4.9, p=0.0007) in patients with inclusion body myositis.

20 thies are polymyositis, dermatomyositis, and inclusion body myositis.

21 otoxic T lymphocyte-mediated autoimmunity in inclusion body myositis.

22 muscle fibers that are specific to sporadic inclusion-body myositis.

23 e new avenues toward the therapy of sporadic inclusion-body myositis.

24 slightly to muscle fiber damage in sporadic inclusion-body myositis.

25 subsets: dermatomyositis, polymyositis, and inclusion-body myositis.

26 ortant clues to the pathogenesis of sporadic inclusion-body myositis.

27 ent concepts of the pathogenesis of sporadic inclusion-body myositis.

28 myopathy, polymyositis, dermatomyositis, and inclusion body myositis].

29 Inclusion body myositis, a chronic inflammatory disorder

30 tal muscle biopsies taken from patients with inclusion body myositis, a degenerative disorder in whic

31 individual cells from patients with sporadic inclusion body myositis, a late-onset inflammatory myopa

32 Muscle biopsies from patients with sporadic inclusion body myositis, a well defined myopathy with ch

33 likely that genetic muscular dystrophies and inclusion body myositis account for some cases of appare

34 There are candidate treatments for inclusion body myositis and a need for additional double

35 retin Val122Ile allele who has both sporadic inclusion body myositis and cardiac amyloidosis.

36 in scattered muscle fibers occur in sporadic inclusion body myositis and clinically similar disorders

37 of mtDNA deletions in patients with sporadic inclusion body myositis and control subjects, mtDNA alte

38 predicted the presence of dendritic cells in inclusion body myositis and of an IFN-alpha/beta respons

39 tically significant benefit in patients with inclusion body myositis and paraproteinemic anti-myelin-

40 Dendritic cells present in inclusion body myositis and polymyositis are primarily m

41 Although inclusion body myositis and polymyositis have been chara

42 ed intramuscular Ag-specific autoimmunity in inclusion body myositis and polymyositis.

43 ociated through genetic analyses to sporadic inclusion body myositis and sarcoidosis.

44 trials in dermatomyositis, polymyositis, and inclusion body myositis and suggests an approach to trea

45 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: Inclusion body myositis and T cell large granular lympho

46 Sporadic inclusion body myositis and the hereditary inclusion bod

47 ripheral neuropathy were also more common in inclusion body myositis and unresponsive polymyositis th

48 d knee extensor involvement was specific for inclusion body myositis and unresponsive polymyositis.

49 y provides insights into the pathogenesis of inclusion-body myositis and concludes that in sIBM one s

50 cell activation in polymyositis and sporadic inclusion-body myositis and the cause of vacuolar degene

51 cot-Marie-Tooth disease 1A, 20 patients with inclusion body myositis, and 29 healthy controls (alloca

52 fibers are common in patients with sporadic inclusion body myositis, and multiple [correction of mut

53 o the disease mechanisms of dermatomyositis, inclusion body myositis, and polymyositis gained from la

54 in muscle in patients with dermatomyositis, inclusion body myositis, and polymyositis.

55 quences of genes that predispose to sporadic inclusion-body myositis, and of human muscle fiber aging

56 In polymyositis and sporadic inclusion-body myositis, antigen-specific and clonally e

57 e diseases dermatomyositis, polymyositis and inclusion body myositis are of unknown cause, but immune

58 The causes of inclusion body myositis are still unknown.

59 forms are polymyositis, dermatomyositis, and inclusion body myositis) are systemic autoimmune disease

60 itochondrial pathology (IM-VAMP), which have inclusion body myositis as a pathologic subtype and are

61 pect that patients with clinical features of inclusion body myositis but lacking histological confirm

62 In polymyositis and sporadic inclusion body myositis, clonal expansion of CD8+ cells

63 In polymyositis and inclusion-body myositis, clonally expanded CD8-positive

64 of the vacuolated muscle fibers of sporadic inclusion body myositis contained well-defined, strongly

65 nd eight studies using various treatments in inclusion body myositis did not show benefit.

66 inclusion-body myositis muscle biopsies with inclusion-body myositis experimental models in tissue cu

67 , we prospectively screened 38 patients with inclusion body myositis for the presence of expanded lar

68 Ultrasound has the ability to differentiate inclusion body myositis from other myopathies.

69 The most important feature distinguishing inclusion body myositis from the other two inflammatory

70 that characterize polymyositis and sporadic inclusion-body myositis from the non-specific, secondary

71 Inclusion body myositis, from its origins 30 years ago,

72 elated with the lower limb components of the inclusion body myositis functional rating score (rho=-0.

73 Most (22/38; 58%) patients with inclusion body myositis had aberrant populations of larg

74 Interest in sporadic inclusion-body myositis has been enhanced by the recent

75 Although most patients with inclusion body myositis have characteristic muscle biops

76 tained muscle biopsy specimens from sporadic inclusion body myositis, hereditary inclusion body myopa

77 Compared with sporadic inclusion body myositis, however, in which the T-cell re

78 histologically distinct patient populations, inclusion body myositis (IBM) and anti-Jo-1-associated m

79 inst a 43 kDa muscle autoantigen in sporadic inclusion body myositis (IBM) and demonstrated the feasi

80 Some of these features are shared with inclusion body myositis (IBM) and this entity cannot be

81 Historically, the diagnosis of sporadic inclusion body myositis (IBM) has required the demonstra

82 Inclusion body myositis (IBM) is a poorly understood aut

83 PURPOSE OF REVIEW: Inclusion body myositis (IBM) is a poorly understood pro

84 Inclusion body myositis (IBM) is an inflammatory muscle

85 Inclusion body myositis (IBM) is an inflammatory myopath

86 Inclusion body myositis (IBM) is an inflammatory myopath

87 ted muscle cells or markers of cell death in inclusion body myositis (IBM) is in distinction to the s

88 Inclusion body myositis (IBM) is the most common muscle

89 IM, their effectiveness for individuals with inclusion body myositis (IBM) remains uncertain.

90 Serum from 70 patients with sporadic inclusion body myositis (IBM) was subjected to agarose g

91 Inclusion body myositis (IBM), a degenerative and inflam

92 New candidate genes have been examined in inclusion body myositis (IBM), and a novel gene transfer

93 polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM), diseases that result from

94 To examine new developments in sporadic inclusion body myositis (IBM), including updated clinica

95 ith dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM), myasthenia gravis, or gen

96 scle wasting in Alzheimer's disease (AD) and inclusion body myositis (IBM), respectively.

97 The pathogenic basis of inclusion body myositis (IBM), the leading muscle degene

98 Inclusion body myositis (IBM), the most common age-relat

99 Inclusion body myositis (IBM), the most common muscle di

100 e consistent histologic findings in sporadic inclusion body myositis (IBM).

101 genesis, diagnosis and treatment of sporadic inclusion body myositis (IBM).

102 arget of serum antibodies from patients with inclusion body myositis (IBM).

103 reatment and serum and imaging biomarkers of inclusion body myositis (IBM).

104 fications: dermatomyositis, polymyositis and inclusion body myositis (IBM).

105 eneration in myositis, focusing primarily on inclusion body myositis (IBM).

106 ease (AD) brain, vacuolated muscle fibers of inclusion-body myositis (IBM) contain abnormally accumul

107 Sporadic inclusion-body myositis (IBM) is the most common muscle

108 are an important diagnostic criterion of the inclusion-body myositis (IBM) muscle biopsy; but, until

109 egulated kinase (ERK) in the pathogenesis of inclusion-body myositis (IBM) was investigated by immuno

110 e describe the occurrence of an inflammatory inclusion body myositis in siblings of a single generati

111 , s-IBM can also occur in families (familial inclusion body myositis), in a pattern analogous to the

112 Sporadic inclusion body myositis is a frequent, acquired, adult-o

113 Inclusion body myositis is much less responsive to immun

114 Although the cause of sporadic inclusion body myositis is unknown, GNE myopathy is asso

115 structs coding for the Alzheimer disease and inclusion body myositis-linked beta-amyloid precursor pr

116 Typical of sporadic inclusion body myositis muscle biopsies are vacuolated m

117 The extent of CD8+ and CD57+ cells in inclusion body myositis muscle correlated with the size

118 ritic cells are abundant in polymyositis and inclusion body myositis muscle.

119 equences, and correlate findings in sporadic inclusion-body myositis muscle biopsies with inclusion-b

120 he recent identification within the sporadic inclusion-body myositis muscle fibers of several abnorma

121 ent may only slightly contribute to sporadic inclusion-body myositis muscle-fiber damage.

122 In polymyositis and inclusion body myositis, muscle fibers are surrounded an

123 In all control and inclusion body myositis or myopathy biopsy specimens, Ap

124 nsubstantiated benefit in some patients with inclusion-body myositis, paraproteinemic IgM demyelinati

125 nflammatory responses that resemble sporadic inclusion body myositis pathology.

126 ge granular lymphocytes into muscle in 15/15 inclusion body myositis patients but in only 1/28 patien

127 s that accumulate in the myocyte vacuoles of inclusion body myositis patients.

128 Inclusion body myositis, polymyositis, and dermatomyosit

129 s of 46 patients newly diagnosed with either inclusion body myositis, polymyositis, or dermatomyositi

130 een reported to be elevated in patients with inclusion-body myositis, polymyositis, dermatomyositis,

131 e cause of vacuolar degeneration in sporadic inclusion-body myositis remain unclear.

132 Treatment of sporadic inclusion-body myositis remains a challenge.

133 opathies (dermatomyositis, polymyositis, and inclusion body myositis) remains obscure.

134 Sporadic inclusion body myositis (s-IBM) is a chronic inflammator

135 , are the characteristic feature of sporadic inclusion body myositis (s-IBM) muscle biopsies, we stud

136 eficiency virus infection (HIV-PM), sporadic inclusion body myositis (s-IBM), dermatomyositis (DM), a

137 atients have a disease identical to sporadic inclusion body myositis (s-IBM).

138 Sporadic inclusion-body myositis (s-IBM) and hereditary inclusion

139 seeking the pathogenic mechanism of sporadic inclusion-body myositis (s-IBM) and hereditary inclusion

140 Sporadic inclusion-body myositis (s-IBM) is the most common progr

141 Sporadic inclusion-body myositis (s-IBM) is the most common progr

142 The hallmark pathologies of sporadic inclusion-body myositis (s-IBM) muscle fibers are autoph

143 in-aggregates are characteristic of sporadic inclusion-body myositis (s-IBM) muscle fibers.

144 ause in the muscle of patients with sporadic inclusion body myositis (sIBM) clonally expanded CD8+ T

145 Sporadic inclusion body myositis (sIBM) is a poorly understood im

146 Sporadic inclusion body myositis (sIBM) is an inflammatory myopat

147 Sporadic Inclusion Body Myositis (sIBM) is the most common acquir

148 the muscle fibers of patients with sporadic inclusion body myositis (sIBM) is unknown.

149 Sporadic inclusion body myositis (sIBM) pathogenesis is unknown;

150 TAR DNA binding protein TDP-43, in sporadic inclusion body myositis (sIBM) sarcoplasm are important

151 myositis (DM) who improved and patients with inclusion body myositis (sIBM) who did not improve after

152 Sporadic inclusion body myositis (sIBM), a common adult-onset myo

153 of the skeletal muscle pathology in sporadic inclusion body myositis (sIBM), have remained elusive.

154 PM), Necrotizing Myositis (NM), and sporadic Inclusion Body Myositis (sIBM).

155 in the pathogenesis of familial and sporadic inclusion body myositis (sIBM).

156 Sporadic inclusion-body myositis (sIBM) is the most common disabl

157 eta-analysis of the apolipoprotein E gene in inclusion body myositis suggests that this gene does not

158 In sporadic inclusion-body myositis the inflammatory cells invade no

159 In many patients with inclusion body myositis, the autoimmune T cell expansion

160 In inclusion body myositis, the HLA 8.1 ancestral haplotype

161 ciated with aging and is related to sporadic inclusion body myositis, the most common acquired muscle

162 Inclusion body myositis, the most common muscle disorder

163 In conceptualizing a treatment for sporadic inclusion-body myositis, the accumulations of amyloid-be

164 Sporadic inclusion-body myositis, the most common muscle disease

165 Sporadic inclusion-body myositis, the most common muscle disease

166 .3]) and MTR reduced compared with controls (inclusion body myositis thigh -1.5 percentage units [pu;

167 ared with controls (regression coefficients: inclusion body myositis thigh 4.0 ms [SE 0.5], calf 3.5

168 We studied 56 patients with sporadic inclusion body myositis, using a combination of clinical

169 In inclusion-body myositis, vacuolar formation with amyloid

170 Inclusion body myositis, which now appears to be the mos

171 ith either Charcot-Marie-Tooth disease 1A or inclusion body myositis who were attending the inherited